1. Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M, Otsuki M. (1996) Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol, 117 (7): 1558-64. [PMID:8730754]

2. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. (1996) Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem, 39: 562-569. [PMID:8558528]

3. Asin KE, Bednarz L, Nikkel AL, Gore Jr PA, Montana WE, Cullen MJ, Shiosaki K, Craig R, Nadzan AM. (1992) Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide. Am J Physiol, 263 (1 Pt 2): R125-35. [PMID:1636779]

4. Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC et al.. (1999) SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther, 289 (2): 742-51. [PMID:10215648]

5. Blevins Jr GT, van de Westerlo EM, Yule DI, Williams JA. (1994) Characterization of cholecystokininA receptor agonist activity by a family of cholecystokininB receptor antagonists. J Pharmacol Exp Ther, 269 (3): 911-6. [PMID:7516969]

6. Broberger C, Holmberg K, Shi TJ, Dockray G, Hökfelt T. (2001) Expression and regulation of cholecystokinin and cholecystokinin receptors in rat nodose and dorsal root ganglia. Brain Res, 903 (1-2): 128-40. [PMID:11382396]

7. Castro JL, Ball RG, Broughton HB, Russell MG, Rathbone D, Watt AP, Baker R, Chapman KL, Fletcher AE, Patel S et al.. (1996) Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem, 39 (4): 842-9. [PMID:8632408]

8. Chang RS, Lotti VJ, Chen TB, Kunkel KA. (1986) Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol, 30 (3): 212-7. [PMID:3018478]

9. Covasa M, Ritter RC. (2005) Reduced CCK-induced Fos expression in the hindbrain, nodose ganglia, and enteric neurons of rats lacking CCK-1 receptors. Brain Res, 1051 (1-2): 155-63. [PMID:16005445]

10. de Weerth A, Pisegna JR, Huppi K, Wank SA. (1993) Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem Biophys Res Commun, 194 (2): 811-8. [PMID:8343165]

11. Dourish CT, Ruckert AC, Tattersall FD, Iversen SD. (1989) Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. Eur J Pharmacol, 173 (2-3): 233-4. [PMID:2625140]

12. Ellenberger HH, Smith FM. (1999) Sulfated cholecystokinin octapeptide in the rat: pontomedullary distribution and modulation of the respiratory pattern. Can J Physiol Pharmacol, 77 (7): 490-504. [PMID:10535709]

13. Elliott RL, Cameron KO, Chin JE, Bartlett JA, Beretta EE, Chen Y, Jardine Pda S, Dubins JS, Gillaspy ML, Hargrove DM et al.. (2010) Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. Bioorg Med Chem Lett, 20 (22): 6797-801. [PMID:20851601]

14. Feifel D, Shilling PD, Kuczenski R, Segal DS. (2003) Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. Neurosci Lett, 348 (3): 147-50. [PMID:12932815]

15. Flynn DL, Villamil CI, Becker DP, Gullikson GW, Moummi C, Yang D. (1992) 1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists. Bioorg Med Chem Lett, 2(10): 1251-1256.

16. Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D. (2000) The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor. Eur J Pharmacol, 400 (2-3): 185-94. [PMID:10988332]

17. Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G. (1993) Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol, 232 (1): 13-9. [PMID:7681406]

18. Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty Jr RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF et al.. (1997) Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem, 40 (17): 2706-25. [PMID:9276016]

19. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA, 87 (17): 6728-32. [PMID:1975695]

20. Innis RB, Snyder SH. (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA, 77 (11): 6917-21. [PMID:6256771]

21. Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K, Yoshida K. (1994) Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. J Pharmacol Exp Ther, 268 (2): 571-5. [PMID:7509389]

22. Iwamoto Y, Yamamoto R, Kuzuya T. (1987) CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini. Pancreas, 2 (1): 85-90. [PMID:2437574]

23. Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. (2001) Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology, 121 (6): 1380-90. [PMID:11729117]

24. Kanagawa K, Nakamura H, Murata I, Yosikawa I, Otsuki M. (2002) Increased gastric acid secretion in cholecystokinin-1 receptor-deficient Otsuka Long-Evans Tokushima fatty rats. Scand J Gastroenterol, 37 (1): 9-16. [PMID:11843043]

25. Kennedy K, Escrieut C, Dufresne M, Clerc P, Vaysse N, Fourmy D. (1995) Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biophys Res Commun, 213 (3): 845-52. [PMID:7654246]

26. Lacourse KA, Lay JM, Swanberg LJ, Jenkins C, Samuelson LC. (1997) Molecular structure of the mouse CCK-A receptor gene. Biochem Biophys Res Commun, 236 (3): 630-5. [PMID:9245702]

27. Latorre M, Bartolomé-Nebreda JM, García-López MT, González-Muñiz R, Herranz R, Del Río J, Cenarruzabeitia E. (2004) Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis. Pharmacology, 72 (2): 68-76. [PMID:15331911]

28. Liddle RA, Goldfine ID, Williams JA. (1984) Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology, 87 (3): 542-9. [PMID:6204904]

29. Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I. (1987) Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung, 37 (11): 1265-8. [PMID:3440035]

30. Marino CR, Leach SD, Schaefer JF, Miller LJ, Gorelick FS. (1993) Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett, 316 (1): 48-52. [PMID:7678554]

31. Mazzocchi G, Malendowicz LK, Aragona F, Spinazzi R, Nussdorfer GG. (2004) Cholecystokinin (CCK) stimulates aldosterone secretion from human adrenocortical cells via CCK2 receptors coupled to the adenylate cyclase/protein kinase A signaling cascade. J Clin Endocrinol Metab, 89 (3): 1277-84. [PMID:15001623]

32. Monstein HJ, Nylander AG, Salehi A, Chen D, Lundquist I, Håkanson R. (1996) Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. Scand J Gastroenterol, 31 (4): 383-90. [PMID:8726308]

33. Moon SJ, An JM, Kim J, Lee SI, Ahn W, Kim KH, Seo JT. (2004) Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells. Eur J Pharmacol, 505 (1-3): 61-6. [PMID:15556137]

34. Moriarty P, Dimaline R, Thompson DG, Dockray GJ. (1997) Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons. Neuroscience, 79 (3): 905-13. [PMID:9219953]

35. Morisset J, Julien S, Lainé J. (2003) Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem, 51 (11): 1501-13. [PMID:14566022]

36. Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L et al.. (2007) 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther, 323 (2): 562-9. [PMID:17684117]

37. Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y et al.. (1994) Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther, 269 (2): 725-31. [PMID:7910212]

38. Nomoto S, Miyake M, Ohta M, Funakoshi A, Miyasaka K. (1999) Impaired learning and memory in OLETF rats without cholecystokinin (CCK)-A receptor. Physiol Behav, 66: 869-872. [PMID:10405116]

39. Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Ryecroft W, Iversen LL, Iversen SD et al.. (1994) Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol, 46 (5): 943-8. [PMID:7969084]

40. Powers SP, Pinon DI, Miller LJ. (1988) Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res, 31 (5): 429-34. [PMID:3410633]

41. Reeve Jr JR, McVey DC, Bunnett NW, Solomon TE, Keire DA, Ho FJ, Davis MT, Lee TD, Shively JE, Vigna SR. (2002) Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58. Pancreas, 25 (3): e50-5. [PMID:12370550]

42. Rettenbacher M, Reubi JC. (2001) Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol, 364 (4): 291-304. [PMID:11683516]

43. Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, Schmassmann A. (1997) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology, 112 (4): 1197-205. [PMID:9098003]

44. Reubi JC, Waser B, Schmassmann A, Laissue JA. (1999) Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?. Int J Cancer, 81 (3): 376-86. [PMID:10209952]

45. Schmitz F, Göke MN, Otte JM, Schrader H, Reimann B, Kruse ML, Siegel EG, Peters J, Herzig KH, Fölsch UR, Schmidt WE. (2001) Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regulatory Peptides, 102: 101-110. [PMID:11730982]

46. Schmitz F, Schrader H, Otte J, Schmitz H, Stüber E, Herzig K, Schmidt WE. (2001) Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul Pept, 101 (1-3): 25-33. [PMID:11495676]

47. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S et al.. (1997) (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem, 40 (3): 331-41. [PMID:9022799]

48. Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA. (1987) Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneimittelforschung, 37 (6): 703-7. [PMID:3663268]

49. Simmons RD, Kaiser FC, Pierson ME, Rosamond JR. (1998) ARL 15849: a selective CCK-A agonist with anorectic activity in the rat and dog. Pharmacol Biochem Behav, 59 (2): 439-44. [PMID:9476993]

50. Singh L, Field MJ, Hill DR, Horwell DC, McKnight AT, Roberts E, Tang KW, Woodruff GN. (1995) Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Eur J Pharmacol, 286 (2): 185-91. [PMID:8605955]

51. Takata Y, Takiguchi S, Funakoshi A, Kono A. (1995) Gene structure of rat cholecystokinin type-A receptor. Biochem Biophys Res Commun, 213 (3): 958-66. [PMID:7654260]

52. Takata Y, Takiguchi S, Kataoka K, Funakoshi A, Miyasaka K, Kono A. (1997) Mouse cholecystokinin type-A receptor gene and its structural analysis. Gene, 187 (2): 267-71. [PMID:9099891]

53. Taniguchi H, Yazaki N, Endo T, Nagasaki M. (1996) Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Eur J Pharmacol, 304 (1-3): 147-54. [PMID:8813597]

54. Tokunaga Y, Cox KL, Coleman R, Concepcion W, Nakazato P, Esquivel CO. (1993) Characterization of cholecystokinin receptors on the human gallbladder. Surgery, 113 (2): 155-62. [PMID:7679224]

55. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L et al.. (1998) Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem, 41 (1): 38-45. [PMID:9438020]

56. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. (1993) Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun, 193 (1): 204-11. [PMID:8503909]

57. Varnavas A, Lassiani L, Valenta V, Berti F, Mennuni L, Makovec F. (2003) Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists. Bioorg Med Chem, 11 (5): 741-51. [PMID:12538004]

58. Wang DQ, Schmitz F, Kopin AS, Carey MC. (2004) Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J Clin Invest, 114 (4): 521-8. [PMID:15314689]

59. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, Slattery T. (1992) Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA, 89 (7): 3125-9. [PMID:1313582]

60. Whited KL, Thao D, Lloyd KC, Kopin AS, Raybould HE. (2006) Targeted disruption of the murine CCK1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function. Am J Physiol Gastrointest Liver Physiol, 291 (1): G156-62. [PMID:16574983]